In summary, rosiglitazone and pioglitazone work together in T2DM through multiple mechanisms, including improved insulin sensitivity, anti-inflammatory, cardiovascular protection, improved lipid metabolism, and protection of islet beta cells. Here, INS is linked to type 2 diabetes mellitus.